Expansion to 45 years old!The State Drug Administration approved ...

On the evening of August 30, the website of the State Drug Administration showed that the indication of Merida's nine -valent papilloma virus vaccine (brewing yeast) (hereinafter referred to as the nine -valent HPV vaccine) was expanded, and the applicable population expanded to a 9 to 45 -year -old female vaccination.

On the same day, Merck also released news, confirming that the new indication of the Nine -Valental HPV vaccine was approved by the State Drug Administration. Subsequently, the "HPV nine -valent vaccine expanded to 9 to 45 years old" quickly appeared on Weibo hot search.

Nine -valent HPV vaccine expands to 45 years old

Cervical cancer is one of the common gynecological malignant tumors. In 2021, ICO/IARC's HPV and related diseases in China show that in 2020, among women 15 to 44 in China, the incidence and mortality rate of cervical cancer ranks third in female tumors.

The HPV vaccine is divided into two -valent, four -valent, and nine valence according to the virus subtypes covered by the vaccine. The age range of each vaccine is slightly different.

The applicable age of the secondary HPV vaccine is 9 to 45 years, covering HPV16 and 18 types; the applicable age of the quadrimal HPV vaccine is 20 to 45 years old, covering HPV6, 11, 16, and type 18; the nine -valent HPV vaccine covers HPV6 with HPV6 Type, 11, 16, 18, 31, 33, type 33, type 45, 52, 58, and type 58 are 16 to 26 years old. Many women have been forced to abandon the nine -valent HPV vaccine because of the age of vaccination.

Earlier, Merck's imported quadrilateral HPV vaccine has expanded in China to 9 to 45 years old. After being approved, the four -valent and nine -valent HPV vaccine of Meroshadong were 9 to 45 years old women.

Tian Anna, a senior vice president of Global Global, said that the expansion of the applied age of the nine -valent HPV vaccine shows the determination of the Chinese government to accelerate the elimination of cervical cancer. Merhadon will increase the HPV vaccine's availability of HPV vaccine by expanding the global production capacity and increasing the supply of the Chinese market.

Nine -valent HPV vaccine is still "hard to find"

At present, the HPV vaccine, which has been approved by my country, includes imported Merosa East Four Valentine Vaccine "Jiada Xiu", Nine -Valental Valles "Jiada Xiu 9"; Grandulosk's two -valent vaccine "Herry"; and domestic 10,000 Thai creature's binary vaccine "Xin Kening" and the binary vaccine of Watson Biological "Wozawa". At present, the nine -valent HPV vaccine is the highest -priced vaccine that can be used to protect HPV viruses on the market. It is also the most sought after vaccine.

However, the penetration rate of the nine -valent HPV vaccine still cannot meet the huge market demand, showing "one shot". Since being approved in China in 2018, Meridon has increased the supply of nine -valent HPV vaccines every year. Zhifei Bio is a domestic agent of the Merck HPV vaccine. Its semi -annual report in 2022 shows that from January to June 2022, the number of nine -valent HPV vaccines was issued 9.2987 million, an increase of 379.34%year -on -year.

Merck also disclosed in the half -year report of 2022. In the first six months of this year, China's sales increased by 87%year -on -year to $ 2.57 billion. Merhadon specifically stated that in recent quarters, the demand for Jiadaxiu in the Chinese market has continued to be high, and it has continuously promoted the company's Chinese business expansion.

Many domestic nine -valent HPV vaccines enter the third phase of the clinical clinical

Except for Merhado, the drug clinical trial registration and information publicity platform shows that in China, 5 companies including Kangle Guardian Wantai Biology, Boyi Biology, Ruico Bio, and Zerun Bio (Watson Biological Subsidies) are underway. Nine -valent HPV vaccine's third phase of clinical trials. Except for Zirun Bio, the upper limit of the clinical trials registered by the remaining four companies are 45 years.

On the morning of August 31, Wantai Biological told reporters that the company's nine -valent HPV vaccine and Merck's nine -valent HPV vaccine have completed the clinical trial site and specimen testing of clinical trials. The bridge is completed in clinical trials.

Liu Jun, deputy chief physician of the Obstetrics and Gynecology Department of Beijing Chaoyang Hospital affiliated to the Capital Medical University, said that it is not recommended to blindly pursue the vaccination of the nine -valent HPV vaccine, and it is also recommended to vaccinate the vaccine in time when he is age. Liu Jun said that the two -price and quadrilateral HP vaccine can also play a good prevention effect. It is not recommended to miss the best prevention timing in order to increase the scope of protection.

Source: Beijing Evening News, People's Daily Science Popularization

Responsible editor: Fang Shujing Su Haojun Chen Zhaoyue

Edit: Zhao Ruoyun

- END -